Peer recovery specialists (PRSs) are substance use service providers with lived experience in recovery. Although a large body of research demonstrates the efficacy of medications for opioid use disorder (MOUD), emerging research suggests PRSs' attitudes toward MOUD are ambivalent or mixed. Few studies have quantitatively assessed factors influencing PRSs' attitudes. This study identifies personal and professional characteristics associated with attitudes toward MOUD among PRSs. PRSs working at publicly funded agencies in Michigan completed a self-administered web-based survey ( = 266, 60.5% women). Surveys assessed socio-demographics, treatment and recovery history, attitudes toward clients, and attitudes toward MOUD. Multiple linear regression was used to identify factors associated with attitudes toward MOUD. A minority of PRSs (21.4%) reported a history of treatment with MOUD, while nearly two-thirds reported current 12-step involvement (62.5%). Compared to PRSs without a history of MOUD treatment, PRSs who had positive (b = 4.71, < .001) and mixed (b = 3.36, = .010) experiences with MOUD had more positive attitudes; PRSs with negative experiences with MOUD had less positive attitudes (b = -3.16, = .003). Current 12-step involvement (b = -1.63, = .007) and more stigmatizing attitudes toward clients (b = -.294, < .001) were associated with less positive attitudes toward MOUD. Black PRSs had less positive attitudes than White PRSs (b = -2.50, = .001), and women had more positive attitudes than men (b = 1.19, = .038). PRSs' attitudes toward MOUD varied based on the nature of their lived experience. Findings highlight considerations for training and supervising PRSs who serve individuals with opioid use disorder.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/00952990.2024.2332597 | DOI Listing |
BMJ Open
January 2025
Center for Pharmacy Innovation and Outcomes, Geisinger, Danville, Pennsylvania, USA
Objectives: This substudy's objectives were to (1) examine the transferability of a four archetype framework (simplified pattern of prototypical features) for patients at high risk for opioid use disorder (OUD) developed from a previous study with a similar population; (2) explore how patient preferences for terminology can inform clinician communication strategies for patients with OUD across archetypes and (3) explore how patient perceptions of opioid risks can inform clinician communication strategies across patient archetypes.
Design: This qualitative study collected data via semistructured phone interviews with patients about views on opioid-related discussions with primary care clinicians. Qualitative data were coded using the Rigorous and Accelerated Data Reduction technique and analysed via iterative inductive/deductive thematic analysis.
J Am Pharm Assoc (2003)
December 2024
Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Georgia, Athens, GA.
Background: Buprenorphine is an effective medication for treating opioid use disorder (OUD) and reducing opioid-related overdose deaths. Community pharmacies are key access points for buprenorphine, with pharmacists well-positioned to dispense and counsel patients on appropriate use. Recent evidence has identified pharmacists' growing engagement in buprenorphine services; yet, access to buprenorphine and related services in community pharmacies remains limited.
View Article and Find Full Text PDFAddict Sci Clin Pract
December 2024
Department of Population and Quantitative Health Sciences, UMass Chan School of Medicine, Worcester, MA, USA.
Introduction: Receipt of medications for opioid use disorder (MOUD) critically reduces opioid-related mortality during the post-incarceration period. Optimal provision of this care to individuals on community supervision (i.e.
View Article and Find Full Text PDFDrug Alcohol Depend
January 2025
Department of Psychiatry, University of Vermont, Burlington, VT 05401, United States; Department of Psychology, University of Vermont, United States.
Background: Among individuals with opioid use disorder (OUD), the prevalence of posttraumatic stress disorder (PTSD) is higher than in the general population. Prolonged exposure (PE) therapy is highly efficacious for improving PTSD symptoms. However, few studies have evaluated PE in individuals receiving medications for OUD (MOUD) and treatment completion rates have been low.
View Article and Find Full Text PDFJ Behav Health Serv Res
January 2025
Alcohol Research Group, Public Health Institute, 6001 Shellmound St #450, Emeryville, CA, 94608, USA.
Medications for alcohol use disorder (MAUD) and opioid use disorder (MOUD) are underutilized evidence-based treatments. While patients often receive treatment in multiple medical treatment settings, it is unknown whether certain treatment settings or combinations of settings are associated with increased receipt of MAUD or MOUD. Data from the cross-sectional 2019 National Survey on Drug Use and Health were used to identify treatment settings where adult respondents received any past year alcohol treatment (n = 476, 33% female) or, separately, opioid treatment (n = 337, 38% female).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!